Esketamine safe, effective for treatment-resistant depression

January 4, 2018

(HealthDay)—Esketamine seems to be efficacious and safe for patients with treatment-resistant depression (TRD), according to a study published online Dec. 27 in JAMA Psychiatry.

Ella J. Daley, M.D., from Janssen Research & Development LLC in Titusville, N.J., and colleagues conducted a phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study to examine the efficacy, safety, and dose-response of intranasal esketamine hydrochloride. A total of 67 adults with a diagnosis of and history of inadequate response to two or more antidepressants (TRD) were randomized and 60 completed two one-week double-blind treatment periods. In period 1, participants were randomized to placebo or esketamine 28, 56, or 84 mg twice weekly (33, 11, 11, and 12 participants, respectively). In period 2, 28 placebo-treated participants were re-randomized to one of the four treatment arms.

The researchers found that the change in Montgomery-Åsberg Depression Rating Scale total score was superior in all three esketamine groups versus placebo (least squares mean difference versus placebo: esketamine 28 mg: −4.2; 56 mg: −6.3; 84 mg: −9.0), with a significant ascending dose-response relationship. Despite reduced dosing frequency in the open-label phase, the improvement in depressive symptoms appeared to be sustained (−7.2).

"In this first clinical study to date of intranasal esketamine for TRD, antidepressant effect was rapid in onset and dose-related," the authors write. "Results support further investigation in larger trials."

Several authors disclosed financial ties to Janssen Research & Development LLC, which funded the study.

Explore further: Opicapone as levodopa adjunct cuts motor fluctuations in Parkinson's disease

More information: Abstract/Full Text
Editorial (subscription or payment may be required)

Related Stories

Opicapone as levodopa adjunct cuts motor fluctuations in Parkinson's disease

December 28, 2016
(HealthDay)—For patients with Parkinson's disease (PD) receiving levodopa therapy and experiencing end-of-dose motor fluctuations, treatment with 50-mg/day opicapone is associated with a reduction in mean daily off-time, ...

Varenicline linked to reduction in heavy drinking in men

December 21, 2017
(HealthDay)—Varenicline is associated with reduced heavy drinking among men and with increased smoking abstinence, according to a study published online Dec. 20 in JAMA Psychiatry.

Intranasal omalizumab does not increase serum IgE levels

November 22, 2017
(HealthDay)—In patients with birch pollen allergy, intranasal administration of omalizumab does not result in relevant change of allergen-specific and total immunoglobulin E (IgE) levels, according to a pilot study published ...

Secukinumab effective for moderate / severe scalp psoriasis

September 29, 2017
(HealthDay)—Secukinumab is safe and effective as a treatment for patients with extensive moderate-to-severe scalp psoriasis, according to a study published in the October issue of the Journal of the American Academy of ...

Naloxegol has no effect on opioid dose in opioid-tied constipation

September 21, 2017
(HealthDay)—For patients with noncancer pain and opioid-induced constipation (OIC), naloxegol has no clinically relevant effect on patient-reported pain levels or mean daily opioid dose, according to research published ...

Lisdexamfetamine dimesylate has early benefit in binge eating

August 4, 2017
(HealthDay)—Lisdexamfetamine dimesylate (LDX) is associated with early improvement in efficacy measures in adults with binge-eating disorder (BED), according to research published in the August issue of the International ...

Recommended for you

People expect their memory to fade as early as their 50s

April 24, 2018
People across the UK expect their memory to worsen in their 50s, according to new research from Heriot-Watt University.

Early childhood interventions show mixed results on child development

April 24, 2018
Early childhood interventions may have some efficacy in boosting measures of child health and development in low income countries, but more work is needed to sort out how to implement these interventions, according to a new ...

Imagining a positive outcome biases subsequent memories

April 24, 2018
Imagining that a future event will go well may lead you to remember it more positively after it's over, according to findings from research published in Psychological Science, a journal of the Association for Psychological ...

Depressed, inactive and out of work—study reveals lives of lonely young adults

April 24, 2018
New research from King's College London shows that lonely young adults are more likely to experience mental health problems and more likely to be out of work than their peers. The study, published today in Psychological Medicine, ...

Sense of control and meaning helps protect women from anxiety

April 24, 2018
People who feel in control of their lives and who find purpose and meaning in life are less likely to have anxiety disorders even when going through the toughest times, according to a study led by the University of Cambridge.

Researchers identify brain mechanism linking PTSD and opioid addiction

April 23, 2018
Researchers at Western University have shown that the recall of traumatic memories enhances the rewarding effects of morphine, shedding light on the neurobiological link between post-traumatic stress disorder (PTSD) and opioid ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.